Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas | Bentham Science
Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas

Author(s): Francesco Bertagna*, Domenico Albano, Elisabetta Cerudelli, Maria Gazzilli, Raffaele Giubbini and Giorgio Treglia

Volume 13, Issue 2, 2020

Page: [94 - 98] Pages: 5

DOI: 10.2174/1874471012666191017093721

Open Access Journals Promotions 2
Abstract

Background: Radiolabeled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors.

Objective: The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data.

Methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas.

Results: Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors.

Conclusion: Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.

Keywords: PSMA, prostate specific membrane antibodies, glioma, glioblastoma, PET, positron emission tomography.

« Previous
Graphical Abstract

[1]
Treglia, G.; Annunziata, S.; Pizzuto, D.A.; Giovanella, L.; Prior, J.O.; Ceriani, L. Detection rate of 18F-Labeled PSMA PET/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Cancers (Basel), 2019, 11(5) E710
[http://dx.doi.org/10.3390/cancers11050710] [PMID: 31126071]
[2]
Wu, H.; Xu, T.; Wang, X.; Yu, Y.B.; Fan, Z.Y.; Li, D.X.; Luo, L.; Yang, X.C.; Jiao, W.; Niu, H.T. Diagnostic performance of 68gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J. Mens Health, 2020, 38(2), 208-219.
[http://dx.doi.org/10.5534/wjmh.180124] [PMID: 31081294]
[3]
Perera, M.; Papa, N.; Roberts, M.; Williams, M.; Udovicich, C.; Vela, I.; Christidis, D.; Bolton, D.; Hofman, M.S.; Lawrentschuk, N.; Murphy, D.G. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol., 2019, S0302-2838(19), 30095-8.
[http://dx.doi.org/10.1016/j.eururo.2019.01.049] [PMID: 30773328]
[4]
Afshar-Oromieh, A.; Avtzi, E.; Giesel, F.L.; Holland-Letz, T.; Linhart, H.G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B.A.; Kratochwil, C.; Weichert, W.; Kopka, K.; Debus, J.; Haberkorn, U. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(2), 197-209.
[http://dx.doi.org/10.1007/s00259-014-2949-6] [PMID: 25411132]
[5]
Kratochwil, C.; Giesel, F.L.; Eder, M.; Afshar-Oromieh, A.; Benešová, M.; Mier, W.; Kopka, K.; Haberkorn, U. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(6), 987-988.
[http://dx.doi.org/10.1007/s00259-014-2978-1] [PMID: 25573634]
[6]
Chang, S.S.; Reuter, V.E.; Heston, W.D.; Bander, N.H.; Grauer, L.S.; Gaudin, P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res., 1999, 59(13), 3192-3198.
[PMID: 10397265]
[7]
Haffner, M.C.; Kronberger, I.E.; Ross, J.S.; Sheehan, C.E.; Zitt, M.; Mühlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X.J.; Geley, S.; Margreiter, R.; Bander, N.H. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol., 2009, 40(12), 1754-1761.
[http://dx.doi.org/10.1016/j.humpath.2009.06.003] [PMID: 19716160]
[8]
Kinoshita, Y.; Kuratsukuri, K.; Landas, S.; Imaida, K.; Rovito, P.M., Jr; Wang, C.Y.; Haas, G.P. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg., 2006, 30(4), 628-636.
[http://dx.doi.org/10.1007/s00268-005-0544-5] [PMID: 16555021]
[9]
Hofman, M.S.; Hicks, R.J.; Maurer, T.; Eiber, M. Prostate-specific membrane antigen pet: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics, 2018, 38(1), 200-217.
[http://dx.doi.org/10.1148/rg.2018170108] [PMID: 29320333]
[10]
Verburg, F.A.; Krohn, T.; Heinzel, A.; Mottaghy, F.M.; Behrendt, F.F. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(10), 1622-1623.
[http://dx.doi.org/10.1007/s00259-015-3065-y] [PMID: 25916744]
[11]
Taywade, S.K.; Damle, N.A.; Bal, C. PSMA expression in papillary thyroid carcinoma opening a new horizon in Management of Thyroid Cancer? Clin. Nucl. Med., 2016, 41(5), e263-e265.
[http://dx.doi.org/10.1097/RLU.0000000000001148] [PMID: 26914556]
[12]
Noss, K.R.; Wolfe, S.A.; Grimes, S.R. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene, 2002, 285(1-2), 247-256.
[http://dx.doi.org/10.1016/S0378-1119(02)00397-9] [PMID: 12039052]
[13]
Bourgeois, S.; Gykiere, P.; Goethals, L.; Everaert, H.; De Geeter, F.W. Aspecific uptake of 68GA-PSMA in paget disease of the bone. Clin. Nucl. Med., 2016, 41(11), 877-878.
[http://dx.doi.org/10.1097/RLU.0000000000001335] [PMID: 27556795]
[14]
Bertagna, F.; Albano, D.; Giovanella, L.; Bonacina, M.; Durmo, R.; Giubbini, R.; Treglia, G. 68Ga-PSMA PET thyroid incidentalomas. Hormones (Athens), 2019, 18(2), 145-149.
[http://dx.doi.org/10.1007/s42000-019-00106-8] [PMID: 30989578]
[15]
Marafi, F.; Sasikumar, A.; Fathallah, W.; Esmail, A. 18F-PSMA 1007 brain pet/ct imaging in glioma recurrence. Clin. Nucl. Med., 2020, 45(1), e61-e62.
[http://dx.doi.org/10.1097/RLU.0000000000002668] [PMID: 31162269]
[16]
Verma, P.; Malhotra, G.; Goel, A.; Rakshit, S.; Chandak, A.; Chedda, R.; Banerjee, S.; Asopa, R.V. Differential uptake of 68ga-psma-hbed-cc (psma-11) in low-grade versus high-grade gliomas in treatment-naive patients. Clin. Nucl. Med., 2019, 44(5), e318-e322.
[http://dx.doi.org/10.1097/RLU.0000000000002520] [PMID: 30829867]
[17]
Kunikowska, J.; Bartosz, K.; Leszek, K. Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy. Eur. J. Nucl. Med. Mol. Imaging, 2018, 45(5), 886-887.
[http://dx.doi.org/10.1007/s00259-018-3934-2] [PMID: 29387926]
[18]
Malik, D.; Kumar, R.; Mittal, B.R.; Singh, H.; Bhattacharya, A.; Singh, S.K. 68Ga-Labeled PSMA uptake in nonprostatic malignancies: has the time come to remove “PS” from PSMA? Clin. Nucl. Med., 2018, 43(7), 529-532.
[http://dx.doi.org/10.1097/RLU.0000000000002103] [PMID: 29688950]
[19]
Salas Fragomeni, R.A.; Pienta, K.J.; Pomper, M.G.; Gorin, M.A.; Rowe, S.P. Uptake of prostate-specific membrane antigen-targeted 18f-dcfpyl in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas. Clin. Nucl. Med., 2018, 43(11), e419-e421.
[http://dx.doi.org/10.1097/RLU.0000000000002280] [PMID: 30247210]
[20]
Sasikumar, A.; Kashyap, R.; Joy, A.; Charan Patro, K.; Bhattacharya, P.; Reddy Pilaka, V.K.; Oommen, K.E.; Pillai, M.R.A. Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma-a pilot study. Clin. Nucl. Med., 2018, 43(9), e304-e309.
[http://dx.doi.org/10.1097/RLU.0000000000002175] [PMID: 29939953]
[21]
Salas Fragomeni, R.A.; Menke, J.R.; Holdhoff, M.; Ferrigno, C.; Laterra, J.J.; Solnes, L.B.; Javadi, M.S.; Szabo, Z.; Pomper, M.G.; Rowe, S.P. Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas. Clin. Nucl. Med., 2017, 42(10), e433-e435.
[http://dx.doi.org/10.1097/RLU.0000000000001769] [PMID: 28737579]
[22]
Sasikumar, A.; Joy, A.; Pillai, M.R.; Nanabala, R.; Anees, K. M.; Jayaprakash, P.G.; Madhavan, J.; Nair, S. Diagnostic value of 68ga psma-11 pet/ct imaging of brain tumors-preliminary analysis. Clin. Nucl. Med., 2017, 42(1), e41-e48.
[http://dx.doi.org/10.1097/RLU.0000000000001451] [PMID: 27846000]
[23]
Unterrainer, M.; Niyazi, M.; Ruf, V.; Bartenstein, P.; Albert, N.L. The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients? Neuro-oncol., 2017, 19(12), 1698-1699.
[http://dx.doi.org/10.1093/neuonc/nox172] [PMID: 29045711]
[24]
Schwenck, J.; Tabatabai, G.; Skardelly, M.; Reischl, G.; Beschorner, R.; Pichler, B.; la Fougère, C. In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(1), 170-171.
[http://dx.doi.org/10.1007/s00259-014-2921-5] [PMID: 25293865]
[25]
Mahzouni, P.; Shavakhi, M. Prostate-specific membrane antigen expression in neovasculature of glioblastoma multiforme. Adv. Biomed. Res., 2019, 8, 18.
[http://dx.doi.org/10.4103/abr.abr_209_18] [PMID: 30993088]
[26]
Matsuda, M.; Ishikawa, E.; Yamamoto, T.; Hatano, K.; Joraku, A.; Iizumi, Y.; Masuda, Y.; Nishiyama, H.; Matsumura, A. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. J. Neurooncol., 2018, 138(3), 581-589.
[http://dx.doi.org/10.1007/s11060-018-2825-5] [PMID: 29524126]
[27]
Nomura, N.; Pastorino, S.; Jiang, P.; Lambert, G.; Crawford, J.R.; Gymnopoulos, M.; Piccioni, D.; Juarez, T.; Pingle, S.C.; Makale, M.; Kesari, S. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int., 2014, 14(1), 26.
[http://dx.doi.org/10.1186/1475-2867-14-26] [PMID: 24645697]
[28]
Saffar, H.; Noohi, M.; Tavangar, S.M.; Saffar, H.; Azimi, S. Expression of prostate-specific membrane antigen (psma) in brain glioma and its correlation with tumor grade. Iran. J. Pathol., 2018, 13(1), 45-53.
[http://dx.doi.org/10.30699/ijp.13.1.45] [PMID: 29731795]
[29]
Wernicke, A.G.; Edgar, M.A.; Lavi, E.; Liu, H.; Salerno, P.; Bander, N.H.; Gutin, P.H. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch. Pathol. Lab. Med., 2011, 135(11), 1486-1489.
[http://dx.doi.org/10.5858/arpa.2010-0740-OA] [PMID: 22032578]

Rights & Permissions Print Cite
Article Metrics
68
3
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy